Substance / Medication

Carmustine

Overview

Active Ingredient
carmustine
RxNorm CUI
2105

Indications

GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade glioma as an adjunct to surgery and radiation, and recurrent glioblastoma as an adjunct to surgery.

Labeler: Azurity Pharmaceuticals, Inc.Updated: 2024-12-05T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Carmustine Wafers Implantation in Patients With Newly Diagnosed High Grade Glioma: Is It Still an Option?
Ricciardi Luca, Manini Ivana, Cesselli Daniela et al. · Front Neurol · 2022
PMID: 35812101Meta-AnalysisFull text (PMC)
Carmustine as a Supplementary Therapeutic Option for Glioblastoma: A Systematic Review and Meta-Analysis.
Xiao Zhi-Ze, Wang Ze-Fen, Lan Tian et al. · Front Neurol · 2020
PMID: 33041980Meta-AnalysisFull text (PMC)
Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis.
Chowdhary Sajeel A, Ryken Timothy, Newton Herbert B · J Neurooncol · 2015
PMID: 25630625Meta-AnalysisFull text (PMC)
Efficacy and safety of carmustine wafers in the treatment of glioblastoma multiforme: a systematic review.
Zhang Yun-Dong, Dai Ruo-Yi, Chen Zhuo et al. · Turk Neurosurg · 2014
PMID: 25269031Meta-Analysis
A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma.
Cardona A F, Rojas L, Wills B et al. · Clin Transl Oncol · 2019
PMID: 30798512Observational
Importance and accuracy of intraoperative frozen section diagnosis of the resection margin for effective carmustine wafer implantation.
Asano Kenichiro, Kurose Akira, Kamataki Akihisa et al. · Brain Tumor Pathol · 2018
PMID: 29948295Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Carmustine (substance)
SNOMED CT
387281007
UMLS CUI
C0007257
RxNorm CUI
2105
Labeler
Azurity Pharmaceuticals, Inc.

Clinical Data

This intervention maps to 11 entities in the Healos knowledge graph.

11
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.